Table 1. Participants in the European Autism Interventions-A Multicentre Study for Developing New
Medications (EU-AIMS) consortium.

Academic centers and research organizations

Companies

Autism Speaks, New York, N.Y.

Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland

Biozentrum of the University of Basel, Basel, Switzerland

Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.

Birkbeck, University of London, London, U.K.

Servier, Neuilly-sur-Seine, France

Campus Bio-Medico University, Rome, Italy

Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.

Central Institute of Mental Health, Mannheim, Germany

Pfizer Inc. (NYSE:PFE), New York, N.Y.

European Molecular Biology Laboratory, Heidelberg, Germany

Galenica Ltd. (SIX:GALN), Berne, Switzerland

French Alternative Energies and Atomic Energy Commission, Saclay, France

deCode genetics ehf, Reykjavik, Iceland

Institute of Education, London, U.K.

NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark

Karolinska Institute, Stockholm, Sweden

 

Max Planck Institute of Experimental Medicine, Goettingen, Germany

 

Pasteur Institute, Paris, France

 

Radboud University Nijmegen, Nijmegen, the Netherlands

 

University Medical Center Utrecht, Utrecht, the Netherlands

 

University of Cambridge, Cambridge, U.K.

 

University of Ulm, Ulm, Germany